JAK class label restrictions are reshaping moderate-disease prescribing
FDA boxed warnings and EMA caution have repositioned JAK inhibitors as later-line agents in rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis - reshaping the practical sequencing decision in moderate disease.
The boxed warnings added to the JAK class - mortality, MACE, malignancy - emerged from the ORAL Surveillance trial and have become the reference frame for how clinicians sequence JAKs against TNF and IL-23 biologics.
In practice, JAKs are now the third or fourth option in moderate rheumatoid arthritis for most prescribers; in atopic dermatitis the picture is more split because the topical route (ruxolitinib cream) sits outside the systemic-warning frame. Step-therapy protocols and prior-authorisation criteria reflect this re-positioning, often requiring documented biologic failure before JAK approval.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.